Clinical Evaluation of the Ethmoid Sinus Spacer

NCT ID: NCT01054703

Last Updated: 2024-08-06

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

14 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-04-01

Study Completion Date

2007-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluation of treatment of the ethmoid sinuses with the Ethmoid Sinus Spacer and Access system

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sinusitis, Chronic Rhinosinusitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ethmoid Sinus Spacer placement

Ethmoid Sinus Spacer and Access System used for the local delivery of Kenalog-40

Group Type EXPERIMENTAL

Ethmoid Sinus Spacer

Intervention Type DEVICE

Ethmoid Sinus Spacer and Access System used for the local delivery of Kenalog-40

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ethmoid Sinus Spacer

Ethmoid Sinus Spacer and Access System used for the local delivery of Kenalog-40

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Acclarent Ethmoid Sinus Spacer and Access System

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age \> 21 years old
2. Both male and female
3. Ethmoid disease on CT scan
4. At least one non-ethmoid sinus requiring treatment
5. Failed medical management and symptomatic

Exclusion Criteria

1. Previous ethmoid surgery
2. Not sufficient room for placement of Spacer
3. Patient requires septoplasty
4. Has received steroid treatment with in 2 weeks
5. Extensive sinonasal osteoneogenesis preventing device placement
6. Sinonasal tumors or obstructive lesions
7. History of facial trauma that distorts sinus anatomy
8. Asthmatic patients with aspirin sensitivity
9. Pregnant or lactating females
Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Acclarent

INDUSTRY

Sponsor Role collaborator

Integra LifeSciences Corporation

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Fred Kuhn, MD

Role: PRINCIPAL_INVESTIGATOR

Georgia Nasal and Sinus Institute

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Georgia Nasal and Sinus Institute

Savannah, Georgia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CPR02082

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Anti-Inflammatory Agent in Sinusitis
NCT02874144 COMPLETED PHASE2